5-HT 4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment

Neuropharmacology

Volumn 61, Issue 1-2, 2011, Pages 69-79

  Shen, Fei ^a   Smith, Jacqueline A M ^a   Chang, Ray ^a   Bourdet, David L ^a   Tsuruda, Pamela R ^a   Obedencio, Glenmar P ^a   Beattie, David T ^a  

^a THERAVANCE INC   (United States)

Author keywords

5 HT 4 receptor agonist; Cholinesterase; Morris water maze; Receptor occupancy; sAPP ; Velusetrag

Indexed keywords

4 [4 [[(2 ISOPROPYL 1H BENZOIMIDAZOLE 4 CARBONYL)AMINO]METHYL] PIPERIDIN 1 YLMETHYL]PIPERADINE 1 CARBOXYLIC ACID METHYL ESTER; 5 FLUORO 2 METHOXY 1H INDOLE 3 CARBOXYLIC ACID 1 [2 (METHYLSULFONAMIDO)ETHYL] 4 PIPERIDINYLMETHYL ESTER; AMYLOID PRECURSOR PROTEIN; DONEPEZIL; PRX 03140; SEROTONIN 4 ANTAGONIST; SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA; TD 8954; UNCLASSIFIED DRUG; VELUSETRAG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LEARNING DISORDER; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HEK293 CELLS; HUMANS; MALE; PROTEIN BINDING; PROTEIN MODIFICATION, TRANSLATIONAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN 5-HT4 RECEPTOR AGONISTS;

EID: 79957832489     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.02.026     Document Type: Article

References (59)

1. + current in mammalian neurons. Proc. Natl. Acad. Sci. U. S. A. 92, 6635-6639.
2. Barthet, G., Carrat, G., Cassier, E., Barker, B., Gaven, F., Pillot, M., Framery, B., Pellissier, L.P., Augier, J., Kang, D.S., Claeysen, S., Reiter, E., Baneres, J.L., Benovic, J.L., Marin, P., Bockaert, J., Dumuis, A., 2009. Beta-arrestin1 p.osphorylation by GRK5 regulates G protein-independent 5-HT4 receptor signalling. EMBO J. 28, 2706-2718.
3. Beattie, D.T., Smith, J.A., 2008. Serotonin pharmacology in the gastrointestinal tract: a review. Naunyn Schmiedebergs Arch. Pharmacol. 377, 181-203.
4. Beattie, D.T., Armstrong, S.R., Shaw, J.P., Marquess, D., Sandlund, C., Smith, J.A., Taylor, J.A., Humphrey, P.P., 2008a. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch. Pharmacol. 378, 139-147.
5. 4 receptor agonist with potential utility in disorders of reduced gastrointestinal motility. Digestive Disease Week abstract #436783 Ref Type: Abstract.
6. Bejar, C., Wang, R.H., Weinstock, M., 1999. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur. J. Pharmacol. 383, 231-240.
7. Birks, J., 2006. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. CD005593.
8. Blondel, O., Gastineau, M., Dahmoune, Y., Langlois, M., Fischmeister, R., 1998. Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. J. Neurochem. 70, 2252-2261. (Pubitemid 28252350)
9. Bonaventure, P., Hall, H., Gommeren, W., Cras, P., Langlois, X., Jurzak, M., Leysen, J.E., 2000. Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse 36, 35-46. (Pubitemid 30134123)
10. Braida, D., Sala, M., 2001. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 7, 369-386. (Pubitemid 34263872)
11. Braida, D., Paladini, E., Griffini, P., Lamperti, M., Maggi, A., Sala, M., 1996. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. Eur. J. Pharmacol. 302, 13-20.
12. Buccafusco, J.J., Terry Jr., A.V., Webster, S.J., Martin, D., Hohnadel, E.J., Bouchard, K.A., Warner, S.E., 2008. The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates. Psychopharmacology (Berl) 199, 481-494. (Pubitemid 351938233)
13. Cachard-Chastel, M., Lezoualc'h, F., Dewachter, I., Delomenie, C., Croes, S., Devijver, H., Langlois, M., Van, L.F., Sicsic, S., Gardier, A.M., 2007. 5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. Br. J. Pharmacol. 150, 883-892.
14. Cheng, Y., Prusoff, W.H., 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
15. Claeysen, S., Faye, P., Sebben, M., Taviaux, S., Bockaert, J., Dumuis, A., 1998. 5-HT4 receptors: cloning and expression of new splice variants. Ann. N. Y Acad. Sci. 861, 49-56.
16. Consolo, S., Arnaboldi, S., Giorgi, S., Russi, G., Ladinsky, H., 1994. 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 5, 1230-1232.
17. De Maeyer, J.H., Schuurkes, J.A., Lefebvre, R.A., 2009. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br. J. Pharmacol. 156, 362-376.
18. Domenech, T., Beleta, J., Fernandez, A.G., Gristwood, R.W., Cruz, S.F., Tolosa, E., Palacios, J.M., 1994. Identification and characterization of serotonin 5-HT4 receptor binding sites in human brain: comparison with other mammalian species. Brain Res. Mol. Brain Res. 21, 176-180.
19. Doody, R.S., Ferris, S.H., Salloway, S., Sun, Y., Goldman, R., Watkins, W.E., Xu, Y., Murthy, A.K., 2009. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 72, 1555-1561.
20. Doran, A., Obach, R.S., Smith, B.J., Hosea, N.A., Becker, S., Callegari, E., Chen, C., Chen, X., Choo, E., Cianfrogna, J., Cox, L.M., Gibbs, J.P., Gibbs, M.A., Hatch, H., Hop, C.E., Kasman, I.N., Laperle, J., Liu, J., Liu, X., Logman, M., Maclin, D., Nedza, F.M., Nelson, F., Olson, E., Rahematpura, S., Raunig, D., Rogers, S., Schmidt, K., Spracklin, D.K., Szewc, M., Troutman, M., Tseng, E., Tu, M., Van Deusen, J.W., Venkatakrishnan, K., Walens, G., Wang, E.Q., Wong, D., Yasgar, A.S., Zhang, C., 2005. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos 33, 165-174. (Pubitemid 40023528)
21. Eglen, R.M., Wong, E.H., Dumuis, A., Bockaert, J., 1995. Central 5-HT4 receptors. Trends Pharmacol. Sci. 16, 391-398.
22. Farlow, M.R., Cummings, J.L., 2007. Effective pharmacologic management of Alzheimer's disease. Am. J. Med. 120, 388-397.
23. Figiel, G.S., Sadowsky, C.H., Strigas, J., Koumaras, B., Meng, X., Gunay, I., 2008. Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study. Prim. Care Companion J. Clin. Psychiatry 10, 291-298.
24. Fontana, D.J., Daniels, S.E., Wong, E.H., Clark, R.D., Eglen, R.M., 1997. The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation. Neuropharmacology 36, 689-696. (Pubitemid 27272115)
25. Goldberg, MR Wsgjlybckm, 2007. TD-5108, a selective 5-HT4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects. Dig. Dis. Week Ref Type: Abstract.
26. Goldberg, M., Li, Y.P., Johanson, J.F., Mangel, A.W., Kitt, M., Beattie, D.T., Kersey, K., Daniels, O., 2010. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT(4) agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment. Pharmacol. Ther. 32, 1102-1112.
27. Grimwood, S., Hartig, P.R., 2009. Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol. Ther. 122, 281-301.
28. Kasa, P., Rakonczay, Z., Gulya, K., 1997. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 52, 511-535.
29. Kirschbaum, K.M., Henken, S., Hiemke, C., Schmitt, U., 2008. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav. Brain Res. 188, 298-303.
30. Lamirault, L., Simon, H., 2001. Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuropharmacology 41, 844-853. (Pubitemid 33001418)
31. Lezoualc'h, F., Robert, S.J., 2003. The serotonin 5-HT4 receptor and the amyloid precursor protein processing. Exp. Gerontol. 38, 159-166.
32. Mahar Doan, K.M., Humphreys, J.E., Webster, L.O., Wring, S.A., Shampine, L.J., Serabjit- Singh, C.J., Adkison, K.K., Polli, J.W., 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303, 1029-1037.
33. Maillet, M., Robert, S.J., Lezoualc'h, F., 2004. New insights into serotonin 5-HT4 receptors: a novel therapeutic target for Alzheimer's disease? Curr. Alzheimer Res. 1, 79-85.
34. Marchetti-Gauthier, E., Roman, F.S., Dumuis, A., Bockaert, J., Soumireu-Mourat, B., 1997. BIMU1 increases associative memory in rats by activating 5-HT4 receptors. Neuropharmacology 36, 697-706. (Pubitemid 27272116)
35. 4 agonist for the treatment of Alzheimer's Disease. In: International Conference on Alzheimer's Disease HT-01-07 (Ref Type: Abstract).
36. Melnikova, I., 2007. Therapies for Alzheimer's disease. Nat. Rev. Drug Discov. 6, 341-342.
37. Mialet, J., Fischmeister, R., Lezoualc'h, F., 2003. Characterization of human 5-HT4(d) receptor desensitization in CHO cells. Br. J. Pharmacol. 138, 445-452.
38. Mnie-Filali, O., Amraei, M.G., Benmbarek, S., Archer-Lahlou, E., Penas-Cazorla, R., Vilaro, M.T., Boye, S.M., Pineyro, G., 2010. Serotonin 4 receptor (5-HT4R) internalization is isoform-specific: effects of 5-HT and RS67333 on isoforms A and B. Cell Signal. 22, 501-509.
39. Mohler, E.G., Shacham, S., Noiman, S., Lezoualc'h, F., Robert, S., Gastineau, M., Rutkowski, J., Marantz, Y., Dumuis, A., Bockaert, J., Gold, P.E., Ragozzino, M.E., 2007. VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology 53, 563-573. (Pubitemid 47284188)
40. Morales-Corraliza, J., Mazzella, M.J., Berger, J.D., Diaz, N.S., Choi, J.H., Levy, E., Matsuoka, Y., Planel, E., Mathews, P.M., 2009. In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing mice. PLoS One 4 (e7134).
41. Moser, P.C., Bergis, O.E., Jegham, S., Lochead, A., Duconseille, E., Terranova, J.P., Caille, D., Berque-Bestel, I., Lezoualc'h, F., Fischmeister, R., Dumuis, A., Bockaert, J., George, P., Soubrie, P., Scatton, B., 2002. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J. Pharmacol. Exp. Ther. 302, 731-741.
42. Onor, M.L., Trevisiol, M., Aguglia, E., 2007. Rivastigmine in the treatment of Alzheimer's disease: an update. Clin. Interv. Aging 2, 17-32.
43. Prvulovic, D., Hampel, H., Pantel, J., 2010. Galantamine for Alzheimer's disease. Expert Opin. Drug Metab. Toxicol. 6, 345-354.
44. Raschetti, R., Albanese, E., Vanacore, N., Maggini, M., 2007. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 4 (e338).
45. Raskind, M.A., Peskind, E.R., Wessel, T., Yuan, W., 2000. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54, 2261-2268. (Pubitemid 30416276)
46. Robert, S.J., Zugaza, J.L., Fischmeister, R., Gardier, A.M., Lezoualc'h, F., 2001. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 276, 44881-44888.
47. Robert, S.J., Lezoualc'h, F., 2008. Distinct functional effects of human 5-HT4 receptor isoforms on beta-amyloid secretion. Neurodegener Dis. 5, 163-165.
48. Russo, O., Cachard-Chastel, M., Riviere, C., Giner, M., Soulier, J.L., Berthouze, M., Richard, T., Monti, J.P., Sicsic, S., Lezoualc'h, F., Berque-Bestel, I., 2009. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease. J. Med. Chem. 52, 2214-2225.
49. Schreiber, R., Vivian, J., Hedley, L., Szczepanski, K., Secchi, R.L., Zuzow, M., van, L.S., Moreau, J.L., Martin, J.R., Sik, A., Blokland, A., 2007. Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur. Neuropsychopharmacol. 17, 277-288.
50. Smith, J.A., Beattie, D.T., Marquess, D., Shaw, J.P., Vickery, R.G., Humphrey, P.P., 2008. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch. Pharmacol. 378, 125-137.
51. Torres, G.E., Chaput, Y., Andrade, R., 1995. Cyclic AMP and protein kinase A mediate 5-hydroxytryptamine type 4 receptor regulation of calcium-activated potassium current in adult hippocampal neurons. Mol. Pharmacol. 47, 191-197.
52. Turner, P.R., O'Connor, K., Tate, W.P., Abraham, W.C., 2003. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol. 70, 1-32.
53. van Marum, R.J., 2009. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis. Treat. 5, 237-247.
54. Van, D.D., Coen, K., De Deyn, P.P., 2008. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacology (Berl) 197, 37-43.
55. 4 receptors. Brit. J. Pharmacol. 150, 782-791.
56. Vincent, G.P., Sepinwall, J.,1992. AF102B, a novel M1agonist, enhanced spatial learning in C57BL/10 mice with a long duration of action. Brain Res. 597, 264-268. (Pubitemid 23003696)
57. Waeber, C., Sebben, M., Grossman, C., Javoy-Agid, F., Bockaert, J., Dumuis, A., 1993. [3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain. Neuroreport 4, 1239-1242. (Pubitemid 23289202)
58. Yamaguchi, T., Suzuki, M., Yamamoto, M., 1997a. Evidence for 5-HT4 receptor involvement in the enhancement of acetylcholine release by p-chloroamphetamine in rat frontal cortex. Brain Res. 772, 95-101. (Pubitemid 27501688)
59. Yamaguchi, T., Suzuki, M., Yamamoto, M., 1997b. Facilitation of acetylcholine release in rat frontal cortex by indeloxazine hydrochloride: involvement of endogenous serotonin and 5-HT4 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 356, 712-720.